Search results

Order by most recent / most popular / relevance

Results: 1-10 of 72

FTC continues to fight controversial reverse payments

Hogan Lovells
-
USA
-
October 27 2011

Over the past few years the Federal Trade Commission has placed a high priority on reining in pharmaceutical litigation settlements that involve payments from the branded company to the generic company, together with an agreed date for generic entry

2010 year in review: key legal and regulatory developments

Allen & Gledhill LLP
-
Singapore
-
December 28 2010

In this last issue for the year 2010, the Allen & Gledhill Legal Bulletin provides an overview of the key developments in 2010

Passing offense by Supreme Court hits healthcare provider post-reform collaboration

Baker & Hostetler LLP
-
USA
-
June 10 2010

Healthcare joint ventures formed by competing providers are likely to come under increased scrutiny following a rare unanimous decision by the U.S. Supreme Court on May 24, 2010

FTC gets shut down - once again - in its bid to change how courts view reverse payment settlements

Sheppard Mullin Richter & Hampton LLP
-
USA
-
June 3 2010

As previously reported on this blog, in January 2009, the Federal Trade Commission launched its latest challenge to the legality of reverse payment settlements in the pharmaceutical industry, this time directed at two settlements involving the brand-name drug AndroGel

Celgene Corporation v Canada (AG) - Supreme Court of Canada grants leave to appeal

Gowling Lafleur Henderson LLP
-
Canada
-
May 21 2010

The Supreme Court of Canada has granted Celgene Corporation's application for leave to appeal the decision of a majority of the Federal Court of Appeal regarding the jurisdiction of the Patented Medicine Prices Review Board

Second Circuit invites rehearing in reverse settlement case

Paul, Weiss, Rifkind, Wharton & Garrison LLP
-
USA
-
May 6 2010

In a recent decision regarding the validity of so-called “reverse settlement” agreements, the U.S. Court of Appeals for the Second Circuit affirmed the dismissal of plaintiffs’ antitrust claims on summary judgment, but took the unusual step of inviting plaintiffs to petition for rehearing by the full Court of Appeals

An overview of Ontario’s proposed drug pricing regulatory reforms

McMillan LLP
-
Canada
-
April 26 2010

Recently announced changes to Ontario's drug pricing laws will potentially have a significant impact on the bottom line of many stakeholders in the Ontario generic drug industry

First PMPRB decision dismissing allegations of excessive pricing

Gowling Lafleur Henderson LLP
-
Canada
-
April 20 2010

The Patented Medicine Prices Review Board ("PMPRB") recently released its decision in the matter of Hoechst Marion Roussel Canada Inc. and the medicine NIOCODERM, a nicotine patch which assists those who are attempting to quit smoking; it is to be publicly posted on the PMPRB website today

Health care reform includes Biologics Price Competition and Innovation Act of 2009

Dechert LLP
-
USA
-
April 16 2010

President Obama signed into law on March 23, 2010 the Patient Protection and Affordable Care Act, which included the Biologics Price Competition and Innovation Act of 2009 ("Biologics Act"

The FTC loses yet another “reverse payment” case

Hogan Lovells
-
USA
-
March 11 2010

On February 22, 2010, the U.S. District Court for the Northern District of Georgia dismissed an antitrust challenge brought by the FTC and private plaintiffs to a so-called “reverse payment” patent settlement relating to the drug Androgel

next >

Search results

FTC continues to fight controversial reverse payments

2010 year in review: key legal and regulatory developments

Passing offense by Supreme Court hits healthcare provider post-reform collaboration

FTC gets shut down - once again - in its bid to change how courts view reverse payment settlements

Celgene Corporation v Canada (AG) - Supreme Court of Canada grants leave to appeal

Second Circuit invites rehearing in reverse settlement case

An overview of Ontario’s proposed drug pricing regulatory reforms

First PMPRB decision dismissing allegations of excessive pricing

Health care reform includes Biologics Price Competition and Innovation Act of 2009

The FTC loses yet another “reverse payment” case

Current Search

Suggested Facets

Author

Firm Name

Jurisdiction

Workarea